TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 177 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,498,440 | -67.3% | 182,292 | -69.4% | 0.01% | -64.7% |
Q1 2024 | $4,589,239 | +18.9% | 595,232 | +38.7% | 0.02% | +6.2% |
Q4 2023 | $3,858,157 | +19.2% | 429,161 | +18.6% | 0.02% | -15.8% |
Q3 2023 | $3,236,217 | -57.7% | 361,993 | -27.3% | 0.02% | -55.8% |
Q2 2023 | $7,653,151 | +4.2% | 498,252 | +52.6% | 0.04% | -14.0% |
Q1 2023 | $7,342,310 | +9.3% | 326,470 | +2.2% | 0.05% | -10.7% |
Q4 2022 | $6,718,118 | +32.5% | 319,454 | +55.3% | 0.06% | +3.7% |
Q3 2022 | $5,070,000 | +57.1% | 205,767 | +54.5% | 0.05% | +80.0% |
Q2 2022 | $3,228,000 | -22.3% | 133,225 | -17.4% | 0.03% | +20.0% |
Q1 2022 | $4,155,000 | -22.8% | 161,243 | -6.9% | 0.02% | -10.7% |
Q4 2021 | $5,379,000 | +122.0% | 173,286 | +73.4% | 0.03% | +64.7% |
Q3 2021 | $2,423,000 | +23.3% | 99,922 | -25.8% | 0.02% | +41.7% |
Q2 2021 | $1,965,000 | -19.6% | 134,661 | +37.6% | 0.01% | -29.4% |
Q1 2021 | $2,444,000 | +717.4% | 97,878 | +792.3% | 0.02% | +466.7% |
Q4 2020 | $299,000 | – | 10,969 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |